AP Biosciences (ROCO:6945) Change In Receivables: NT$-1.54 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6945 AP Biosciences Inc ROCO:6945
21 GF Score
Price NT$95.80
! 1 Warning Sign
View Full Analysis

What is AP Biosciences Change In Receivables?

AP Biosciences ROCO:6945 +0.52% 21 Change In Receivables is NT$-1.54 Mil as of Jun. 2026. GuruFocus rates ROCO:6945 with a GF Score™ of 21/100. The stock has 1 warning sign investors should review.

AP Biosciences's change in receivables for the quarter that ended in Jun. 2026 was NT$1.50 Mil. It means AP Biosciences's Accounts Receivable declined by NT$1.50 Mil from Mar. 2026 to Jun. 2026 .

AP Biosciences's change in receivables for the fiscal year that ended in Dec. 2025 was NT$-3.39 Mil. It means AP Biosciences's Accounts Receivable increased by NT$3.39 Mil from Dec. 2024 to Dec. 2025 .

AP Biosciences's Accounts Receivable for the quarter that ended in Jun. 2026 was NT$0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. AP Biosciences's liquidation value for the three months ended in Jun. 2026 was NT$2,107.87 Mil.

AP Biosciences  (ROCO:6945) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

AP Biosciences's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/0*91
=

2. In Ben Graham's calculation of liquidation value, AP Biosciences's accounts receivable are only considered to be worth 75% of book value:

AP Biosciences's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=2194.516-86.645+0.75 * 0+0.5 * 0
=2,107.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AP Biosciences Change In Receivables Related Terms

AP Biosciences Change In Receivables Historical Data

* Premium members only.

The historical data trend for AP Biosciences's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AP Biosciences Change In Receivables Chart

AP Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial 0.09 -0.12 -2.31 0.75 -3.39

AP Biosciences Quarterly Data
Dec20 Dec21 Dec22 Jun23 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.18 -0.91 -1.06 -1.08 1.50
ROCO:6945
21GF Score
AP Biosciences Inc ROCO:6945
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AP Biosciences Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-1.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of NT$-1.54 Mil mean?
AP Biosciences (ROCO:6945) has a Change In Receivables of NT$-1.54 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for AP Biosciences and its competitors.
Is AP Biosciences' Change In Receivables too high?
AP Biosciences' current Change In Receivables is NT$-1.54 Mil. Overall, AP Biosciences has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does AP Biosciences' Change In Receivables compare to VRTX and REGN?
AP Biosciences' Change In Receivables of NT$-1.54 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for AP Biosciences and its competitors. AP Biosciences's current Change In Receivables is NT$-1.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AP Biosciences stock overvalued right now?
AP Biosciences (ROCO:6945) has a current Change In Receivables of NT$-1.54 Mil. The current Change In Receivables is NT$-1.54 Mil. AP Biosciences' overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For AP Biosciences (ROCO:6945), the current Change In Receivables is NT$-1.54 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AP Biosciences Business Description

Address No. 3, Park Street, 17th Floor, Taipei, TWN
AP Biosciences Inc is a clinical-stage bispecific antibody new drug research and development company. It has developed a series of antibody and protein lead drugs through a self-designed technology platform for unmet medical needs, focusing on Specific targets associated with diseases to deliver safe, effective and cost-effective medicines.
21GF Score

Get the complete analysis for ROCO:6945

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$95.80
Price